Eli Lilly Wins Halt to Drug Discount Dispute Resolution Rule (1)

Eli Lilly & Co. has stopped the U.S. government from requiring drugmakers to administratively resolve disputes with medical providers over a federal drug discount program, convincing a federal court that the HHS didn’t comply with procedural standards when it adopted the dispute resolution rule.

The 340B Drug Pricing Program requires drugmakers participating in Medicare Part B and Medicaid to offer outpatient drugs to public and not-for-profit hospitals, community centers, and other federally funded clinics serving low-income patients at steeply discounted prices.

Eli Lilly is likely to prove the Department of Health and Human Services violated the Administrative Procedure Act by ...